Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Distinct Genetic Alterations Drive Cushing Disease Versus Silent Corticotroph Adenomas.
Journal: The Journal of clinical endocrinology and metabolism
Published: January 26, 2026
Liraglutide and Exenatide in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes.
Journal: Pharmaceutics
Published: November 17, 2025
Non-recurrent mutations and copy number changes predominate pituitary adenoma genomes.
Journal: European journal of endocrinology
Published: December 12, 2024
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients.
Journal: Clinical lung cancer
Published: December 04, 2024
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 08, 2024
Response to Crizotinib After Entrectinib Resistance in ROS1-Rearranged, MET-Amplified Lung Adenocarcinoma.
Journal: JCO precision oncology
Published: October 07, 2024
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 10, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 11, 2024
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 20, 2023
Powassan Virus Infections: A Systematic Review of Published Cases.
Journal: Tropical medicine and infectious disease
Published: November 08, 2023
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Journal: Cancer discovery
Published: October 16, 2023
Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival.
Journal: European radiology
Published: December 28, 2022
Last Updated: 09/26/2026